Key Highlights
- Lantern to offer Pelago’s personalized SUD treatment starting next year.
- Comprehensive care covers all substances and severities, including alcohol, opioids, and tobacco.
- Pelago integrates telemedicine with in-person treatment backed by peer-reviewed research.
- Addresses a critical gap for the 49 million U.S. workers with SUD or mental health illnesses.
- Lantern’s curated network ensures high-quality, accessible care nationwide.
Source: Direct
Notable Quotes
- “This partnership between Pelago and Lantern marks a significant step forward in delivering comprehensive, high-quality care solutions for employers and their members.” — Frank Jennings, President at Pelago
- “Through Pelago, our clients will soon have access to tailored SUD programs, provided both in-person or via telehealth, that’s backed by science and proven to improve health outcomes.” — Dickon Waterfield, President at Lantern
Why This Matters
The partnership between Lantern and Pelago represents a transformative approach to addressing substance use disorders (SUDs), a critical and growing concern among the U.S. workforce. With 49 million adults affected by SUD or mental health illness, and only a fraction receiving adequate employer support, this collaboration bridges a significant healthcare gap. By combining Lantern’s specialty care expertise with Pelago’s innovative substance use treatment, employers can now provide their teams with personalized, effective care, resulting in better health outcomes and enhanced workforce well-being.
Related

#192 – Panna Sharma, CEO & President at Lantern Pharma
Watch https://youtu.be/sI69Ve990YE Listen https://open.spotify.com/episode/0v9K95KbFqiFHnEWAAL8DU?si=AkCsdh4OSWScCUrtWyXhYw&dl_branch=1 Episode Details Our guest: Panna Sharma, CEO & President at Lantern Pharma "Lantern Pharma, Inc. is a clinical stage pharmaceutical company developing new classes of precision cancer drugs with novel mechanisms of action, and also rescuing or revitalizing abandoned or failed cancer drugs using machine learning techniques,…

New Lantern Launches AI Radiology Resident with $19M Series A
Key Highlights New Lantern raises $19M Series A funding, led by Benchmark, totaling $23M raised to date. Platform automates 25% of radiology workflows, with a vision to automate up to 90% over time. Radiologists reclaim hours by focusing on critical tasks, improving patient care speed and increasing earnings. First cloud-native AI radiology suite, acting…

WellSky & Vytalize Health Forge Partnership
Key Highlights WellSky's Next Generation Provider solution will be utilized by Vytalize Health to foster acute and post-acute provider communication and coordination.The partnership aims to enhance patient outcomes by ensuring seamless information flow and guiding patients to high-performing post-acute facilities.WellSky's extensive network includes over 2,000 acute and 130,000 post-acute providers, facilitating better care management…